Krajina: Írsko
Jazyk: angličtina
Zdroj: HPRA (Health Products Regulatory Authority)
TACROLIMUS
McDermott Laboratories Ltd t/a Gerard Laboratories
L04AD02
TACROLIMUS
0.5 Milligram
Capsules Hard
Product subject to prescription which may not be renewed (A)
Calcineurin inhibitors
Authorised
2011-06-17
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT TACROLIMUS MYLAN 0.5 MG HARD CAPSULES TACROLIMUS MYLAN 1 MG HARD CAPSULES TACROLIMUS MYLAN 5 MG HARD CAPSULES tacrolimus READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Tacrolimus Mylan is and what it is used for 2. What you need to know before you take Tacrolimus Mylan 3. How to take Tacrolimus Mylan 4. Possible side effects 5. How to store Tacrolimus Mylan 6. Contents of the pack and other information 1. WHAT TACROLIMUS MYLAN IS AND WHAT IT IS USED FOR Tacrolimus Mylan contains the active substance tacrolimus which is an immunosuppressant. Following your organ transplant (e.g. liver, kidney, heart), your body’s immune system will try to reject the new organ. Tacrolimus Mylan is used to control your body’s immune response enabling your body to accept the transplanted organ. Tacrolimus Mylan is often used in combination with other medicines that also suppress the immune system. You may also be given Tacrolimus Mylan for an ongoing rejection of your transplanted liver, kidney, heart or other organ when any previous treatment you were taking was unable to control this immune response after your transplantation. [http://xpil Prečítajte si celý dokument
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Tacrolimus Mylan 0.5 mg hard capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each Tacrolimus Mylan 0.5 mg hard capsule contains 0.5 mg tacrolimus Excipient(s) with known effect: Each Tacrolimus Mylan 0.5 mg hard capsule contains 109.1 mg lactose anhydrous For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsule, hard. Tacrolimus Mylan 0.5 mg hard capsule: Ivory cap and ivory body hard shell capsules with white powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prophylaxis of transplant rejection in liver, kidney or heart allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Tacrolimus Mylan therapy requires careful monitoring by adequately qualified and equipped personnel. The medicinal product should only be prescribed, and changes in immunosuppressive therapy initiated, by physicians experienced in immunosuppressive therapy and the management of transplant patients. Inadvertent, unintentional or unsupervised switching of immediate- or prolonged-release formulations of tacrolimus is unsafe. This can lead to graft rejection or increased incidence of side effects, including under- or over- immunosuppression, due to clinically relevant differences in systemic exposure to tacrolimus. Patients should be maintained on a single formulation of tacrolimus with the corresponding daily dosing regimen; alterations in formulation or regimen should only take place under the close supervision of a transplant specialist (see sections 4.4 and 4.8). Following conversion to any alternative formulation, therapeutic drug monitoring must be performed and dose adjustments made to ensure that systemic Prečítajte si celý dokument